Why Perfluorocarbon Gas in the Anterior Segment Is Indefensible — and Why Continuing to Use It Borders on Malpractice
A Surgeon’s Perspective After 30 Years of Warning the Field
Long before endothelial-sparing surgery became mainstream, and long before DSAEK and DMEK entered routine practice, the ophthalmic community already had clear scientific evidence that certain intraocular gases—particularly perfluorocarbon gases (C₂F₆, C₃F₈, C₄F₁₀, and SF₆)—were toxic to the anterior segment.
In 1995, during my residency, I presented a controlled animal study at ARVO titled:
“Anterior Segment Toxicity of Intraocular Gases”
(M.D. Duplessie, D. Chow, J.H. Bates)
This work was done before I had become a corneal surgeon—yet it produced results so stark and so consistent that they should have permanently shaped surgical decision-making from that moment forward.
And yet, nearly three decades later, many of the same gases continue to be introduced—intentionally into the anterior chamber during corneal transplantation and other anterior segment procedures.
The consequences are predictable.
The science is clear.
And the continued use of these gases in the anterior chamber is, at minimum, negligent.
At worst, it crosses the line into malpractice.
I. The Evidence: My 1995 ARVO Study
Study Design
70 New Zealand albino rabbits
Divided into groups receiving:
Air, C₂F₆, C₃F₈, C₄F₁₀, SF₆
Gas bubbles were kept small (<10 mm) to avoid pupillary block and ensure normal IOP
Follow-up: slit lamp, pachymetry, endothelial microscopy, clinical photos, and histology
Key Findings
Air caused no damage.
No corneal edema; 0% lens changes.
Every perfluorocarbon gas caused significant toxicity, including:
90% cataract formation
Ulceration of the anterior lens capsule
Focal corneal stromal edema
Endothelial cell proliferation, guttata, and abnormal Descemet-like material
Conjunctival congestion
Damage even without direct gas–tissue contact
Toxicity was not due to pressure
IOP was carefully controlled and remained normal.
Expansile potential was ruled out
Even small, non-expansile volumes produced injury.
Conclusion in 1995
“This study indicates significant anterior segment toxicity from perfluorocarbons. Direct contact is not required to produce lens changes.”
In animal research standards—ophthalmic or otherwise—when every gas in a chemical class demonstrates toxicity to the same structures, the scientific community usually draws a simple conclusion:
You stop putting that substance in that part of the body.
II. Independent Evidence Since 1995 Confirms the Same Toxicity
Although 1995 study remains one of the only systematic analyses across all major gases, the last three decades of ophthalmic literature have repeatedly echoed the same themes:
1. Endothelial Cell Toxicity
Multiple human and animal studies have demonstrated:
Apoptosis of endothelial cells
Structural irregularities
Permanent endothelial loss
Delayed corneal decompensation
This aligns directly with the histology documented in 1995.
2. Cataract Formation
In phakic eyes, cataractogenesis after anterior chamber PFC exposure is now widely reported
Our 90% cataract rate was not an artifact—it was a warning.
3. Inflammatory Response
Retained PFC droplets—whether liquid or gas—can induce:
Foreign-body reaction
Pigment deposition
Chronic flare
Granulomatous inflammation
Most clinicians have encountered this but often misattribute it.
4. Higher Endothelial Loss in Lamellar Transplants
In DMEK/DSAEK literature:
SF₆ and C₃F₈ are consistently associated with higher endothelial cell loss compared to air.
Some studies directly attribute damage to gas exposure, not graft handling.
5. Modern Confirmation in Animal Models
Contemporary rabbit and primate studies continue to find:
Corneal edema
Endothelial apoptosis
Stromal disruption
…when perfluorocarbon gases enter the anterior chamber.
Nowhere in the last 30 years is there a comparable study suggesting that these gases are safe for the anterior segment.
III. Lamellar Surgery Shows the Stakes Clearly
Supported by my textbook chapter
Lamellar keratoplasty
Lamellar keratoplasty is technically challenging precisely because:
The corneal endothelium is irreplaceable.
Descemet’s membrane is unforgiving.
Even small toxic insults accelerate endothelial loss.
My chapter outlines the precision required for lamellar surgery and the catastrophic consequences of endothelial stress.
The posterior corneal surface is invisible surgically and already at risk.
Deliberately adding a known toxin to that environment violates the principles on which lamellar surgery was built.
IV. The Ethical Boundary: When Known Toxicity Meets Modern Practice
In both surgical science and biomedical ethics, there is a simple rule:
If an intervention fails preclinical animal toxicity testing, it cannot ethically be introduced into human subjects.
Yet perfluorocarbon gases—which failed every endpoint of the 1995 toxicity study—continue to be used in the anterior segment, often with the justification of convenience or tradition.
But clinical convenience does not nullify toxicology.
Tradition does not override pathology.
And decades of repeated endothelial cell loss, corneal decompensation, and cataract formation cannot be attributed to “normal surgical variation.”
The ethical and medicolegal reality is this:
The toxicity is known.
The mechanism is consistent.
The human outcomes match the animal outcomes.
The risk is avoidable.
Continuing to use a substance with three decades of documented anterior segment toxicity—after controlled animal studies predicted exactly these outcomes—is not evidence-based medicine.
It is negligence.
V. Why This Matters Now
Corneal transplantation has evolved:
Grafts are thinner
Endothelium is more precious
Small injuries cause large consequences
The entire lamellar revolution—which I helped accelerate—depends on protecting the endothelium at all costs.
Introducing a substance known to injure the endothelium, ulcerate the lens capsule, and induce inflammatory changes is the opposite of modern corneal surgery.
VI. Final Statement
Perfluorocarbon use in the anterior chamber is not a matter of preference. It is a matter of science.
The data—my own from 1995 and the global literature since—show:
Consistent endothelial toxicity
High cataract formation
Persistent inflammatory response
Histopathologic damage in every model tested
No proven safe exposure threshold
No study demonstrating anterior segment safety
Science does not contradict itself here.
The only contradiction is between toxicology and the continued use of these gases in certain corneal procedures.
For 30 years, I have warned the field:
These agents are toxic to the front of the eye.
The current literature only strengthens that conclusion.
My commitment to patients—and to my colleagues—is unchanged:
If a surgeon uses a substance that has repeatedly been proven toxic to the cornea and lens, and if safer alternatives exist, the surgeon is responsible for the injury that follows.
And that is why perfluorocarbon gas use in the anterior segment is not just outdated.
It is indefensible.